China Palmoplantar Pustulosis (PPP) Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2020
  • Country Level
  • 350 Pages
  • No of Tables: 56
  • No of Figures: 43

China Palmoplantar Pustulosis (PPP) Market, By Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Type (Diagnosis and Treatment), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Home Healthcare), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) Industry Trends and Forecast to 2027

China Market Analysis and Insights: China Palmoplantar Pustulosis (PPP) Market

Palmoplantar pustulosis (PPP) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.1% in the forecast period of 2020 to 2027 and is expected to reach USD 102.19 million by 2027 from USD 69.64 million in 2019.

Increasing prevalence of palmoplantar pustulosis and increasing women population are the major drivers which propelled the demand of the market in the forecast period.

Palmoplantar pustulosis (PPP) comprises features such increasing need for better therapeutics options will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative drugs and therapies which is expected to provide various other opportunities in the palmoplantar pustulosis market. However, lack of awareness and side effect of PPP treatment expected to restraint the market growth in the forecast period.

The palmoplantar pustulosis (PPP) report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

China Palmoplantar Pustulosis (PPP) Market

China Palmoplantar Pustulosis (PPP) Market Scope and Market Size

The palmoplantar pustulosis (PPP) market is categorized into seven notable segments which are based on basis of disease type, severity, type, population type, route of administration, end user and distribution channel.

  • On the basis of disease type, the palmoplantar pustulosis (PPP) market is segmented into type A and type B. In 2020, type B is dominating the market as it is one of the frequently occurring forms of palmoplantar pustulosis disease and has been reported to associate with several forms of psoriasis.
  • On the basis of severity, the palmoplantar pustulosis (PPP) market is segmented into mild-moderate and moderate-severe. In 2020, moderate-severe is dominating the market as most of the people reported to have symptoms associated with moderate severe forms along with this moderate severe form required long term therapies in order to achieve accurate treatment.
  • On the basis of type, the palmoplantar pustulosis (PPP) market is segmented into diagnosis and treatment. In 2020, diagnosis segment is dominating the market because patient suffering from PPP have to undergone multiple time diagnosis involving skin biopsy, skin test among others due to association of multiple types of symptoms.
  • On the basis of population type, the palmoplantar pustulosis (PPP) market is segmented into children and adults. In 2020, adults segment is dominating as palmoplantar pustulosis reported to affect individuals at the age of 30-50 years of age and children are less prone to palmoplantar pustulosis.
  • On the basis of route of administration, the palmoplantar pustulosis (PPP) market is segmented into oral, topical and parenteral. In 2020, parenteral segment is dominating because parenteral formulations directly reach the systemic circulation and provides rapid and effective result, moreover several biological therapies involving adalimumab among others are also available in injectable form.
  • On the basis of end user, the palmoplantar pustulosis (PPP) market is segmented into hospitals, specialty clinics, diagnostic centers and home healthcare. In 2020, diagnostic centers are dominating due to increasing demand of exact diagnosis as several symptoms associated with the palmoplantar pustulosis disease.
  • On the basis of distribution channel, the palmoplantar pustulosis (PPP) market is segmented into direct tender, hospital pharmacies, retail pharmacies and online pharmacies. In 2020, hospital pharmacies is dominating the market as the patients suffering from PPP frequently visits hospital in order to achieve accurate treatment and hence procures drug and therapies from nearby hospital pharmacies.

Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Palmoplantar pustulosis (PPP) Market 

Palmoplantar pustulosis (PPP) market also provides you with detailed market analysis for every country growth in palmoplantar pustulosis sales, impact of advancement in the palmoplantar pustulosis and changes in regulatory scenarios with their support for the palmoplantar pustulosis (PPP) market. The data is available for historic period 2010 to 2018. 

Competitive Landscape and Palmoplantar pustulosis (PPP) Market Share Analysis

Palmoplantar pustulosis (PPP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Palmoplantar pustulosis (PPP) market.

The major players covered in the report are Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Pharmaceuticals, Inc.  (A Subsidiary of Johnson & Johnson Services, Inc.), AbbVie Inc., Bristol-Myers Squibb Company, Perrigo Company plc, ingenus Pharmaceuticals, F. Hoffmann-La Roche Ltd, WOCKHARDT, Bausch Health Companies Inc., ALEOR Dermaceuticals Limited, Mylan N.V., Amneal Pharmaceuticals LLC., Xiromed and Encube Ethicals, among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the palmoplantar pustulosis (PPP) market.

  • In January 2019, Zydus Pharmaceuticals, Inc. (A subsidiary of Zydus Cadila) acquired the Heinz India which is a leading player in healthcare domain and has a strong distribution network over the 800 distributors. This acquisition thus boosted the company’s product sales and allowed it to generate more revenue.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the palmoplantar pustulosis (PPP) market which also provides the benefit for organisation to improve their offering for palmoplantar pustulosis.  

Customization Available: China Palmoplantar Pustulosis (PPP) Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, PIPELINE ANALYSIS

TABLE 2 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 3 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE TYPE B PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE TYPE A PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY SEVERITY,2019-2027 (USD MILLION)

TABLE 6 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE MODERATE TO SEVER PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE MILD TO MODERATE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIAGNOSIS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 10 U.S., EUROPE, CHINA & JAPAN DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPETREATMENT PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 12 U.S., EUROPE, CHINA & JAPAN TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 13 U.S., EUROPE, CHINA & JAPAN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 14 U.S., EUROPE, CHINA & JAPAN IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 15 U.S., EUROPE, CHINA & JAPAN TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 16 U.S., EUROPE, CHINA & JAPAN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 17 U.S., EUROPE, CHINA & JAPANTOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 18 U.S., EUROPE, CHINA & JAPAN SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 19 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY POPULATION TYPE ,2019-2027 (USD MILLION)

TABLE 20 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE ADULTS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE ADULTS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 23 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 24 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 25 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 26 U.S., EUROPE, CHINA & JAPAN TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 U.S., EUROPE, CHINA & JAPAN ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 28 U.S., EUROPE, CHINA & JAPAN TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 29 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIAGNOSTIC CENTERS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 31 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE SPECIALTY CLINICS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOSPITALS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOME HEALTHCARE PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE HOSPITAL PHARMACIES PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 36 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE RETAIL PHARMACIES PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 U.S., JAPAN, CHINA & U.S., JAPAN, CHINA & EUROPE DIRECT TENDERS PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 U.S., EUROPE, CHINA & JAPAN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 39 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISEASE TYPE 2018-2027 (USD MILLION)

TABLE 40 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY SEVERITY 2018-2027 (USD MILLION)

TABLE 41 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 42 CHINA DIAGNOSIS IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 43 CHINA TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 44 CHINA BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 45 CHINA IL INHIBITORS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 46 CHINA TNF-ALPHA BLOCKERS IN BIOLOGICAL THERAPY IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 47 CHINA TOPICAL TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 48 CHINA TOPICAL TREATMENT BY VITAMIN D DERIVATIVES IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 49 CHINA SYSTEMIC TREATMENT IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 50 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY POPULATION TYPE 2018-2027 (USD MILLION)

TABLE 51 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 52 CHINA PARENTERAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 53 CHINA TOPICAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 54 CHINA ORAL ADMINISTRATION IN PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (USD MILLION)

TABLE 55 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 56 CHINA PALMOPLANTAR PUSTULOSIS (PPP) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions